Correction to: The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma (OncoImmunology, (2013), 2, 5, (e24270), 10.4161/onci.24270);The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma

OncoImmunology

Volumn 2, Issue 5, 2013, Pages

  Agarwal, Sumit ^a   Saini, Shikha ^a   Parashar, Deepak ^a   Verma, Archana ^a   Sinha, Abhilasha ^a   Jagadish, Nirmala ^a   Batra, Aruna ^b   Suri, Sushma ^b   Gupta, Anju ^c   Ansari, Abdul S ^d   Lohiya, Nirmal Kumar ^d   Suri, Anil ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b SAFDARJUNG HOSPITAL   (India)

^c Vidyasagar Institute of Mental Health and Neurosciences Hospital   (India)

^d UNIVERSITY OF RAJASTHAN   (India)

Author keywords

AKAP4; Cancer testis antigen; Immunotherapy; Ovarian serous carcinoma; Vaccine

Indexed keywords

A KINASE ANCHOR PROTEIN 4; A KINASE ANCHOR PROTEIN 4 ANTIBODY; CANCER TESTIS ANTIGEN; MESSENGER RNA; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

A KINASE ANCHOR PROTEIN 4 GENE; ADENOFIBROMA; ARTICLE; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PAPILLARY CARCINOMA; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN TARGETING;

EID: 84880916857     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2021.1921437     Document Type: Erratum

References (28)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138
2. Suri A, Saini S, Sinha A, Agarwal S, Verma A, Parashar D, et al. Cancer testis antigens: A new paradigm for cancer therapy. Oncoimmunology 2012; 1:1194-6; PMID:23170277; http://dx.doi.org/10.4161/onci.20686
3. Garg M, Chaurasiya D, Rana R, Jagadish N, Kanojia D, Dudha N, et al. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clin Cancer Res 2007; 13:1421-8; PMID:17332284; http://dx.doi. org/10.1158/1078-0432.CCR-06-2340
4. Garg M, Kanojia D, Khosla A, Dudha N, Sati S, Chaurasiya D, et al. Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma. Cancer Res 2008; 68:8240-8; PMID:18922895; http://dx.doi.org/10.1158/0008-5472.CAN-08-1708
5. Kanojia D, Garg M, Gupta S, Gupta A, Suri A. Spermassociated antigen 9, a novel biomarker for early detection of breast cancer. Cancer Epidemiol Biomarkers Prev 2009; 18:630-9; PMID:19190149; http://dx.doi.org/10.1158/1055-9965.EPI-08-0629
6. Garg M, Kanojia D, Salhan S, Suri S, Gupta A, Lohiya NK, et al. Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer 2009; 115:2671-83; PMID:19326449; http://dx.doi.org/10.1002/cncr.24293
7. Garg M, Kanojia D, Suri S, Gupta S, Gupta A, Suri A. Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer. J Clin Endocrinol Metab 2009; 94:4613-8; PMID:19820019; http://dx.doi.org/10.1210/jc.2009-0703
8. Kanojia D, Garg M, Saini S, Agarwal S, Kumar R, Suri A. Sperm associated antigen 9 expression and humoral response in chronic myeloid leukemia. Leuk Res 2010; 34:858-63; PMID:20138665; http://dx.doi.org/10.1016/j.leukres.2010.01.017
9. Kanojia D, Garg M, Gupta S, Gupta A, Suri A. Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol 2011; 178:1009-20; PMID:21356354; http://dx.doi.org/10.1016/j. ajpath.2010.11.047
10. Yu P, Yan L, Zhang H, Lin X, Zhao X. Expression and clinical significance of sperm-associated antigen 9 in patients with endometrial carcinoma. Int J Gynecol Cancer 2012; 22:87-93; PMID:22146769; http://dx.doi.org/10.1097/IGC.0b013e3182370f2e
11. Ghafouri-Fard S, Modarressi MH. Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med 2009; 12:395-404; PMID:19566358
12. Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, et al. NY-ESO-1 and LAGE-1 cancertestis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003; 63:6076-83; PMID:14522938
13. Chiriva-Internati M, Yu Y, Mirandola L, Jenkins MR, Chapman C, Cannon M, et al. Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One 2010; 5:e10471; PMID:20485677; http://dx.doi.org/10.1371/journal. pone.0010471
14. Mohapatra B, Verma S, Shankar S, Suri A. Molecular cloning of human testis mRNA specifically expressed in haploid germ cells, having structural homology with the A-kinase anchoring proteins. Biochem Biophys Res Commun 1998; 244:540-5; PMID:9514854; http://dx.doi.org/10.1006/bbrc.1998.8079
15. Vermeij R, Daemen T, de Bock GH, de GraeffP, Leffers N, Lambeck A, et al. Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin Dev Immunol 2010; 2010:1505-15; PMID:20885926; http://dx.doi.org/10.1155/2010/891505
16. Chiriva-Internati M, Raffaele F, Yu Y, Hamrick C, Gagliano N, Grizzi F, et al. AKAP4: a novel cancer testis antigen for multiple myeloma. Br J Haematol 2008; 140:465-68; http://dx.doi.org/10.1111/j.1365-2141.2007.06940.x
17. Chiriva-Internati M, Yu Y, Mirandola L, D'Cunha N, Hardwicke F, Cannon MJ, et al. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate 2012; 72:12-23; PMID:21520158; http://dx.doi.org/10.1002/pros.21400
18. Taylor SE, Kirwan JM. Ovarian cancer: current management and future directions. Obstetrics, Gynaecol Reprod Med 2012; 22:33-7; http://dx.doi.org/10.1016/j.ogrm.2011.11.003
19. Kepp O, Tesniere A, Zitvogel L, Kroemer G. The immunogenicity of tumor cell death. Curr Opin Oncol 2009; 21:71-6; PMID:19125021; http://dx.doi.org/10.1097/CCO.0b013e32831bc375
20. Scudellari M. A ballsy search for cancer targets. Nat Med 2011; 17:916-8; PMID:21818078; http://dx.doi.org/10.1038/nm0811-916
21. Tammela J, Uenaka A, Ono T, Noguchi Y, Jungbluth AA, Mhawech-Fauceglia P, et al. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Int J Oncol 2006; 29:903-10; PMID:16964386
22. Valmori D, Qian F, Ayyoub M, Renner C, Merlo A, Gnjatic S, et al. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Clin Cancer Res 2006; 12:398-404; PMID:16428478; http://dx.doi.org/10.1158/1078-0432.CCR-05-1902
23. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102:18538-43; PMID:16344461; http://dx.doi.org/10.1073/pnas.0509182102
24. Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, et al. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLADR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire. Clin Cancer Res 2009; 15:4467-74; PMID:19531622; http://dx.doi.org/10.1158/1078-0432.CCR-09-0582
25. Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 2008; 14:2740-8; PMID:18451240; http://dx.doi.org/10.1158/1078-0432.CCR-07-4619
26. Lee JH, Schütte D, Wulf G, Füzesi L, Radzun HJ, Schweyer S, et al. Stem-cell protein Piwil2 is widely expressed in tumors and inhibits apoptosis through activation of Stat3/Bcl-XL pathway. Hum Mol Genet 2006; 15:201-11; PMID:16377660; http://dx.doi.org/10.1093/hmg/ddi430
27. Sharma S, Qian F, Keitz B, Driscoll D, Scanlan MJ, Skipper J, et al. A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. Gynecol Oncol 2005; 99:183-8; PMID:16005946; http://dx.doi.org/10.1016/j. ygyno.2005.06.006
28. Tammela J, Jungbluth AA, Qian F, Santiago D, Scanlan MJ, Keitz B, et al. SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Cancer Immun 2004; 4:10; PMID:15487888